Liposomal adjuvants for human vaccines

Expert Opinion on Drug Delivery

Volumn 13, Issue 6, 2016, Pages 807-816

  Alving, Carl R ^a   Beck, Zoltan ^a,b   Matyas, Gary R ^a   Rao, Mangala ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Adjuvant; immunostimulation; liposomes; vaccine

Indexed keywords

LIPOSOME; PHOSPHORYL LIPID A; VACCINE; VIROSOME; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT;

HUMAN; LIPOSOMAL DELIVERY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VIRUS PARTICLE; ANIMAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; HUMANS; LIPOSOMES; VACCINATION; VACCINES;

EID: 84959052838     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1151871     Document Type: Review

References (91)

1. S.A.Plotkin Vaccines: the fourth century. Clin Vaccine Immunol. 2009;16(12):1709–1719. doi:10.1128/CVI.00290-09.
2. J.L.Excler, M.L.Robb, J.H.Kim. Prospects for a globally effective HIV-1 vaccine. Vaccine. 2015;33(Suppl 4):D4–D12. doi:10.1016/j.vaccine.2015.03.059.
3. Guideline on adjuvants for vaccines for human use. London, UK: European Medicines Agency Committee for Medicinal Products for Human Use, 20Jan 2005. [cited 2015 Sept 230]. Available from: http://vaccine-safety-training.org/tl_files/vs/pdf/EMEA.pdf.
4. M.C.Hardegree, M.Pittman. Influence of antigens on release of free fatty acids from Arlacel A (mannide monooleate). Proc Soc Exp Biol Med. 1966;123(1):179–184.
5. C.R.Alving, G.R.Matyas, O.Torres, et al. Adjuvants for vaccines to drugs of abuse and addiction. Vaccine. 2014;32(42):5382–5389.
6. L.A.Brito, D.T.O’Hagan. Designing and building the next generation of improved vaccine adjuvants. J Control Release. 2014;190:563–579.• Places the development of liposome-based adjuvants in the greater context of the development of commercial vaccine adjuvants.
7. R.Glück, C.Moser, I.C.Metcalfe. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin Biol Ther. 2004;4(7):1139–1145. doi:10.1517/14712598.4.7.1139.
8. C.Moser, M.Müller, M.D.Kaeser, et al. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12(7):779–791.•• Detailed review of history of intellectual property development and clinical use of virosome adjuvant/antigen technology, particularly as it relates to influenza virus.
9. N.Garçon, M.Van Mechelen. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10(4):471–486.• Summary of the GSK liposome vaccine technology.
10. M.Henriksen-Lacey, K.S.Korsholm, P.Andersen, et al. Liposomal vaccine delivery systems. Expert Opin Drug Deliv. 2011;8(4):505–519.
11. C.R.Alving, M.Rao, N.J.Steers, et al. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines. 2012;11(6):733–744.•• Detailed review of history, intellectual properties, and activities of lipid A, MPLA, and liposomes containing lipid A.
12. D.S.Watson, A.N.Endsley, L.Huang. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine. 2012;30(13):2256–2272.• Detailed review that includes a summary of preclinical research and clinical development of various types of liposomes as adjuvants.
13. Y.Perrie, E.Kastner, R.Kaur, et al. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum Vaccin Immunother. 2013;9(6):1374–1381.• Provides a reasoned algorithm for the initiation and development of cationic liposomal adjuvants.
14. R.A.Schwendener. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014;2(6):159–182. doi:10.1177/2051013614541440.
15. A.D.Bangham, M.M.Standish, J.C.Watkins. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–252.• Original description of liposomes.
16. A.D.Bangham. Membrane models with phospholipids. Prog Biophys Mol Biol. 1968;18:29–95.
17. S.M.Gruner, P.R.Cullis, M.J.Hope, et al. Lipid polymorphism: the molecular basis of nonbilayer phases. Annu Rev Biophys Biophys Chem. 1985;14:211–238. doi:10.1146/annurev.bb.14.060185.001235.
18. D.M.Small. The physical states of lipids: solids, mesomorphic states, and liquids. In: D.M.Small, editor. The physical chemical of lipids. From alkanes to phospholipids. New York: Plenum; 1986. p. 43–87.• Comprehensive and authoritative description of the biophysical characteristics and chemistry of liposomal lipids.
19. G.Sessa, G.Weissmann. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res. 1968;9(3):310–318.
20. D.F.H.Wallach. Method of producing high-aqueous volume multilamellar vesicles. US4855090. 1989.
21. R.K.Gupta, C.L.Varanelli, P.Griffin, et al. Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens. Vaccine. 1996;14(3):219–225.
22. J.Davidsen, I.Rosenkrands, D.Christensen, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6ʹ-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 2005;1718(1–2):22–31.
23. E.M.Agger, I.Rosenkrands, J.Hansen, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 2008;3(9):e3116. doi:10.1371/journal.pone.0003116.
24. J.T.Van Dissel, S.A.Joosten, S.T.Hoff, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014;32(52):7098–7107.
25. T.Storni, T.M.Kündig, G.Senti, et al. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57(3):333–355. doi:10.1016/j.addr.2004.09.008.
26. Z.Beck, G.R.Matyas, C.R.Alving. Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim Biophys Acta. 2015;1848(3):775–780. doi:10.1016/j.bbamem.2014.12.005.
27. Z.Beck, G.R.Matyas, R.Jalah, et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;pii: S0264-410X(15)01244-X. doi:10.1016/j.vaccine.2015.09.001. Epub ahead of print.• Description of physical characteristics and adjuvant properties of ALF and ALFQ.
28. R.Glück, R.Mischler Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them. Publication number WO 92/19267. 1992.
29. R.Glück. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine. 1992;10(13):915–919.• Original description of virosome adjuvant technology.
30. R.Glück. Liposomal presentation of antigens for human vaccines. Pharm Biotechnol. 1995;6:325–345.
31. R.Zurbriggen. Immunostimulating reconstituted influenza virosomes. Vaccine. 2003 Feb 14;21(9–10):921–924.
32. C.Herzog, K.Hartmann, V.Künzi, et al. Eleven years of inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27(33):4381–4387. doi:10.1016/j.vaccine.2009.05.029.
33. D.Felnerova, J.F.Viret, R.Glück, et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15(6):518–529. doi:10.1016/j.copbio.2004.10.005.
34. S.A.Mymetics [Internet]. 2015. [cited 2015 Sep23]. Available from: http://www.mymetics.com/
35. T.Kamphuis, T.Meijerhof, T.Stegmann, et al. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012;7(5):e36812. doi:10.1371/journal.pone.0036812.
36. T.Kamphuis, T.Stegmann, T.Meijerhof, et al. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Respir Viruses. 2013;7(6):1227–1236.
37. M.Just, R.Berger, H.Dreschsler, et al. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine. 1992;10(11):737–739.
38. L.Loutan, P.Bovier, B.Althaus, et al. Inactivated virosome hepatitis A vaccine. Lancet. 1994;343(8893):322–324.
39. R.Glück, R.Mischler, B.Finkel, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 1994;344(8916):160–163.
40. I.A.De Bruijn, J.Nauta, W.C.Cramer, et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine. 2005;23(Suppl 1):S39–49.
41. B.Mengiardi, R.Berger, M.Just, et al. Virosomes as carriers for combined vaccines. Vaccine. 1995;13(14):1306–1315.
42. G.K.Pedersen, H.Sjursen, J.K.Nøstbakken, et al. Matrix M™ adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother. 2014;10(8):2408–2416.
43. R.Glück, R.Mischler, S.Brantschen, et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest. 1992;90(6):2491–2495.
44. R.Mischler, I.C.Metcalfe. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002;20 Suppl 5:B17–23.
45. R.Gasparini, D.Amicizia, P.L.Lai, et al. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V ® and Fluad ®) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study. Hum Vaccin Immunother. 2013;9(1):144–152.
46. H.Lal, A.L.Cunningham, O.Godeaux, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096.
47. D.G.HeppnerJr, K.E.Kester, C.F.Ockenhouse, et al. Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005;23(17–18):2243–2250.
48. S.Casares, T.D.Brumeanu, T.L.Richie. The RTS, S malaria vaccine. Vaccine. 2010;28(31):4880–4894. doi:10.1016/j.vaccine.2010.05.033.
49. C.R.Alving, R.L.Richards, J.Moss, et al. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine. 1986;4(3):166–172.• Original description of use of liposomes containing MPLA for malaria vaccine.
50. R.L.Richards, M.D.Hayre, W.T.Hockmeyer, et al. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun. 1988;56(3):682–686.
51. J.F.Young, W.R.Ballou, W.T.Hockmeyer. Developing a human malaria sporozoite vaccine. Microb Pathog. 1987;2(4):237–240.
52. W.R.Ballou, S.L.Hoffman, J.A.Sherwood, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987;1(8545):1277–1281.
53. L.F.Fries, D.M.Gordon, R.L.Richards, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A. 1992;89(1):358–362.•• The first phase I liposome human vaccine clinical trial. It describes the safety of nonpyrogenic liposomes containing 2.2 mg of MPLA as an adjuvant for a malaria vaccine containing a recombinant protein with a repeat sequence of CSP.
54. P.Vandepapeliere Vaccine compositions comprising a Saponin adjuvant. US patent application 20110206758. August 25, 2011.• US patent application publication that contains a detailed description of the composition and preparation of AS01B.
55. C.R.Kensil, U.Patel, M.Lennick, et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991;146(2):431–437.•• Original description of QS21 as an adjuvant.
56. C.W.Cluff. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 2010;667:111–123. doi:10.1007/978-1-4419-1603-7_10.
57. N.Garçon, J.Silvano, C.F.Kuper, et al. Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys. J Appl Toxicol. 2015. doi:10.1002/jat.3167. Epub ahead of print
58. E.Destexhe, D.Stannard, O.K.Wilby, et al. Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 cancer immunotherapeutic, a therapeutic vaccine for cancer treatment. Reprod Toxicol. 2015;51:90–105. doi:10.1016/j.reprotox.2014.12.009.
59. L.Segal, V.Roger, C.Williams, et al. Effects of adjuvant systems on the cardiovascular and respiratory functions in telemetered conscious dogs and anaesthetised rats. Regul Toxicol Pharmacol. 2015;73(1):116–125.
60. G.J.Vosika, C.Barr, D.Gilbertson. Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother. 1984;18(2):107–112.
61. R.L.Richards, G.M.SwartzJr, C.Schultz, et al. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine. 1989;7(6):506–512.
62. C.R.Alving. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology. 1993;187(3–5):430–446. doi:10.1016/S0171-2985(11)80355-4.
63. D.C.Waite, E.W.Jacobson, F.A.Ennis, et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine. 2001;19(28–29):3957–3967.
64. I.Mbawuike, Y.Zang, R.B.Couch. Humoral and cell-mediated immune responsesof humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine. 2007;25(17):3263–3269. doi:10.1016/j.vaccine.2007.01.073.
65. K.Takayama, E.Ribi, J.L.Cantrell. Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res. 1981;41(7):2654–2657.• Original description of monophosphoryl lipid A.
66. E.Ribi, K.Amano, J.L.Cantrell, et al. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol Immunother. 1982;12:91–96. doi:10.1007/BF00205365.
67. N.Qureshi, K.Takayama, E.Ribi. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem. 1982;257(19):11808–11815.•• Detailed purification of monophosphoryl lipid A.
68. C.R.Alving. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann N Y Acad Sci. 1995;754:143–152.
69. C.R.Alving. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine. 2002;20(Suppl 3):S56–S64.
70. G.R.Matyas, J.M.Muderhwa, C.R.Alving. Oil-in-water liposomal emulsions for vaccine delivery. Methods Enzymol. 2003;373:34–50. doi:10.1016/S0076-6879(03)73003-1.
71. M.Rao, K.K.Peachman, Q.Li, et al. Highly effective generic adjuvant systems for orphan or poverty-related vaccines. Vaccine. 2011;29(5):873–877.
72. M.J.McElrath. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol. 1995;6(6):375–385.
73. D.G.Heppner, D.M.Gordon, M.Gross, et al. Safety, immunogenicity, and efficacy of plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis. 1996;174(2):361–366.
74. W.D.Zollinger, J.G.Babcock, E.E.Moran, et al. Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. Vaccine. 2012;30(4):712–721.
75. F.L.Richards, J.R.Hailey, J.E.Egan, et al. Intramuscular fate and local effects of liposomes as carriers for drugs and vaccines. In: P.N.Shek, editor. Liposomes in biomedical applications. Singapore: Harwood Academic Publishers; 1995. p. 167–178.
76. T.Yokochi, Y.Inoue, J.Yokoo, et al. Retention of bacterial lipopolysaccharide at the site of subcutaneous injection. Infect Immun. 1989;57(6):1786–1791.
77. S.Rerks-Ngarm, P.Pitisuttithum, S.Nitayaphan, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220.
78. A.Muhs, D.T.Hickman, M.Pihlgren, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A. 2007;104(23):9810–9815.
79. AC Immune technology [Internet]. 2015 [cited 2015 Sep 25]. Available from: http://www.acimmune.com/
80. M.Henriksen-Lacey, V.W.Bramwell, D.Christensen, et al. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release. 2010;142(2):180–186.
81. M.Henriksen-Lacey, D.Christensen, V.W.Bramwell, et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release. 2010;145(2):102–108.
82. M.Henriksen-Lacey, A.Devitt, Y.Perrie. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release. 2011;154(2):131–137. doi:10.1016/j.jconrel.2011.05.019.
83. M.Henriksen-Lacey, D.Christensen, V.W.Bramwell, et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N’,N’-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol Pharm. 2011;8(1):153–161.
84. R.Kaur, V.W.Bramwell, D.J.Kirby, et al. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release. 2012;158(1):72–77.
85. R.Kaur, V.W.Bramwell, D.J.Kirby, et al. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response. J Control Release. 2012;164(3):331–337. doi:10.1016/j.jconrel.2012.07.012.
86. E.Kastner, M.J.Hussain, V.W.Bramwell, et al. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study. J Pharm Pharmacol. 2015;67(3):450–463.
87. K.Y.Chung, E.M.Coyle, D.Jani, et al. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine. 2015;33(32):3953–3962.
88. N.Principi, S.Esposito. Adjuvanted influenza vaccines. Hum Vaccin Immunother. 2012;8(1):59–66. doi:10.4161/hv.8.1.18011.
89. R.J.Cox, G.Pedersen, A.S.Madhun, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine. 2011;29(45):8049–8059.
90. I.Leroux-Roels, S.Forgus, F.De Boever, et al. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2013;31(17):2196–2206.
91. J.Montoya, J.A.Solon, S.R.Cunanan, et al. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol. 2013;33(8):1360–1375.